Physician profile
Peter B Dragisic
NPI 1205932332
$11,529.93
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,628 · 2020: $2,486 · 2021: $2,684 · 2022: $1,909 · 2023: $349 · 2024: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,426.82 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,253.64 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,144.81 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,011.41 | 2019-2024 | Synthroid |
| Novo Nordisk INC | $864.70 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $830.93 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.64 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $588.65 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $441.06 | 2019-2022 | |
| Allergan, INC. | $407.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $382.29 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $375.25 | 2019-2022 | |
| Esperion Therapeutics, INC. | $283.76 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $252.00 | 2019-2024 | |
| Amgen INC. | $187.18 | 2019-2023 | Otezla, Repatha |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $185.64 | 2021-2024 | Camzyos, Eliquis |
| Mylan Specialty L.P. | $160.13 | 2019-2024 | Yupelri |
| Horizon Therapeutics Plc | $114.92 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.33 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $112.53 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.36 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $101.34 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $92.12 | 2022-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $75.44 | 2021 | |
| Eisai INC. | $64.10 | 2019 | |
| Astellas Pharma US INC | $43.87 | 2022-2024 | Veozah |
| Almatica Pharma LLC | $41.26 | 2021-2022 | |
| Adlon Therapeutics L.P. | $37.93 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $37.32 | 2020 | |
| Ironwood Pharmaceuticals, INC | $32.34 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $31.84 | 2019-2020 | |
| Alfasigma USA, INC. | $27.03 | 2021-2022 | |
| Exact Sciences Corporation | $25.08 | 2024 | Cologuard Collection Kit |
| Penumbra, INC. | $16.71 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dragisic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.